GP
AVEO

GLG Partners’s AVEO Pharmaceuticals, Inc. AVEO Stock Holding History

GLG Partners’s Portfolio AVEO Stock Details AVEO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q4 		$70K Buy
+2,520
New +$78.2K ﹤0.01% 434

Other funds holding AVEO

NMC
NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return
PC
Polar Capital London, United Kingdom $13.5B AUM 55.9% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
6CM
683 Capital Management New York $2.04B AUM 94.26% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
SFM
Sphera Funds Management Tel Aviv, Israel $767M AUM 119.71% 1-Year Est. Return

GLG Partners's AVEO Position: Q4 2017 in Review

GLG Partners opened a new position in AVEO Pharmaceuticals, Inc. (AVEO) in Q4 2017: 2,520 shares worth $70K. The stake represents ﹤0.01% of the portfolio and ranks #434 among its holdings.

84 funds tracked by Wall St. Rank hold AVEO as of Q4 2017.

  • GLG Partners held 2,520 shares of AVEO Pharmaceuticals, Inc. worth $70K as of Q4 2017.
  • AVEO Pharmaceuticals, Inc. was a new GLG Partners position in Q4 2017.
  • AVEO Pharmaceuticals, Inc. made up ﹤0.01% of GLG Partners's portfolio in Q4 2017, its #434 holding.
  • 84 funds tracked by Wall St. Rank held AVEO Pharmaceuticals, Inc. as of Q4 2017.

Based on GLG Partners's 13F filing for Q4 2017, filed 14 Feb 2018.